Video by PCR via YouTube
Go to Source

Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24.
TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR’s safety and efficacy, highlighting its less invasive nature. Further investigations will explore long-term outcomes and potential subgroup benefits.

More news about the ACC.24 on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2024/ACC/PCR-ACC-Scientific-Sessions

Go to Source